The trading price of Lineage Cell Therapeutics Inc (AMEX:LCTX) closed higher on Monday, December 09, and closing at $0.60, 2.30% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $0.575 and $0.6128. In examining the 52-week price action we see that the stock hit a 52-week high of $1.61 and a 52-week low of $0.50. Over the past month, the stock has lost -33.79% in value.
Lineage Cell Therapeutics Inc, whose market valuation is $135.47 million at the time of this writing, is expected to release its quarterly earnings report in January. Investors’ optimism about the company’s current quarter earnings report is understandable.
On the technical side, indicators suggest LCTX has a 100% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
A quick review shows that LCTX’s price is currently -13.25% off the SMA20 and -25.09% off the SMA50. The RSI metric on the 14-day chart is currently showing 40.05, and weekly volatility stands at 9.68%. When measured over the past 30 days, the indicator reaches 10.62%. Lineage Cell Therapeutics Inc (AMEX:LCTX)’s beta value is currently sitting at 1.16, while the Average True Range indicator is currently displaying 0.07.
To see how Lineage Cell Therapeutics Inc stock has been performing in comparison to its peers in the industry, here are the numbers: LCTX stock’s performance was 2.30% in the latest trading, and -43.99% in the past year.
An evaluation of the daily trading volume of Lineage Cell Therapeutics Inc (AMEX:LCTX) indicates that the 3-month average is 1.39 million. However, this figure has increased over the past 10 days to an average of 5.26.
Currently, records show that 220.42 million of the company’s shares remain outstanding. The insiders hold 0.66% of outstanding shares, whereas institutions hold 43.28%. The stats also highlight that short interest as of 2024-10-31, stood at 15.94 million shares, resulting in a short ratio of 35.21 at that time. From this, we can conclude that short interest is 1089.00 of the company’s total outstanding shares. It is noteworthy that short shares in October were up slightly from the previous month’s figure, which was 15.22 million. However, since the stock’s price has seen -45.02% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
